Cargando…

Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)

The impact of baseline versus intercurrent steroids on the efficacy of upfront chemotherapy plus pembrolizumab (CT-ICI) for advanced non-small cell lung cancer (NSCLC) patients is unclear. We conducted a retrospective study on metastatic NSCLC patients treated with upfront CT-ICI at our institution...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Giglio, Andrea, Aprile, Marta, Di Federico, Alessandro, Sperandi, Francesca, Melotti, Barbara, Gelsomino, Francesco, Ardizzoni, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499348/ https://www.ncbi.nlm.nih.gov/pubmed/36142204 http://dx.doi.org/10.3390/ijms231810292

Ejemplares similares

The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy
por: De Giglio, Andrea, et al.
Publicado: (2022)

Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes
por: Di Federico, Alessandro, et al.
Publicado: (2022)

Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis
por: Di Federico, Alessandro, et al.
Publicado: (2021)

EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature
por: Di Federico, Alessandro, et al.
Publicado: (2022)

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)
por: De Giglio, Andrea, et al.
Publicado: (2020)

New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event
por: Lamberti, Giuseppe, et al.
Publicado: (2020)

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
por: De Giglio, Andrea, et al.
Publicado: (2021)

Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma
por: Comito, Francesca, et al.
Publicado: (2022)

Cerebral Meningitis (Intercurrent)
por: Hay, Walter
Publicado: (1875)

Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term
por: Cortelazzo, Sergio, et al.
Publicado: (2021)

Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer
por: Parisi, Claudia, et al.
Publicado: (2020)

Intercurrent Remedies for Chronic Diseases
Publicado: (1889)

Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
por: Moliner, L., et al.
Publicado: (2023)

Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients
por: De Giglio, Andrea, et al.
Publicado: (2022)

Intercurrent events in clinical research: the norm, not the exception
por: Rojas-Saunero, L. Paloma, et al.
Publicado: (2022)

Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy?
por: Merkin, Ross D., et al.
Publicado: (2023)

High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC
por: Grambozov, Brane, et al.
Publicado: (2022)

Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia
por: Loong, Herbert H., et al.
Publicado: (2022)

Chemo-immunotherapy for metastatic non-squamous NSCLC in a patient with HIV infection: A case report
por: Inno, Alessandro, et al.
Publicado: (2023)

Immunity against Helminths: Interactions with the Host and the Intercurrent Infections
por: Moreau, Emmanuelle, et al.
Publicado: (2010)

Rethinking intercurrent events in defining estimands for tuberculosis trials
por: Pham, Tra My, et al.
Publicado: (2022)

The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
por: Lamberti, Giuseppe, et al.
Publicado: (2020)

The Physical Examination of the Chest in Pulmonary Consumption and Its Intercurrent Diseases
Publicado: (1861)

Retrospective study on intercurrent pancreatitis with Babesia gibsoni infection in dogs
por: MASUDA, Misa, et al.
Publicado: (2019)

Diathesis and Cachexiæ during Intercurrent Attacks—The Importance of Their Recognition and Treatment
por: Winston, Geo. H.
Publicado: (1890)

Translating questions to estimands in randomized clinical trials with intercurrent events
por: Stensrud, Mats J., et al.
Publicado: (2022)

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
por: Sisi, Monia, et al.
Publicado: (2022)

Local ablative therapies in oligometastatic NSCLC-upfront or outback?—a narrative review
por: Tjong, Michael C., et al.
Publicado: (2021)

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
por: Sisi, Monia, et al.
Publicado: (2023)

Monitoring tumor growth rate to predict immune checkpoint inhibitors’ treatment outcome in advanced NSCLC
por: Dall’Olio, Filippo G., et al.
Publicado: (2022)

Intercurrent and opportunistic infections in patients treated with biological agents: study hypothesis
por: Popescu, Ramona Ștefania, et al.
Publicado: (2014)

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors
por: Dall’Olio, Filippo G., et al.
Publicado: (2020)

Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study
por: Lang, David, et al.
Publicado: (2020)

Impact of intercurrent illness on calcium homeostasis in children with hypoparathyroidism: a case series
por: Chinoy, A, et al.
Publicado: (2017)

Chemo-Radio-Immunotherapy for NSCLC III: ESR/ATS Thresholds for DL(CO) Correlate with Radiation Dosimetry and Pneumonitis Rate
por: Stana, Markus, et al.
Publicado: (2023)

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
por: Gelsomino, Francesco, et al.
Publicado: (2021)

Case Report: An “Immune-Cold” EGFR Mutant NSCLC With Strong PD-L1 Expression Shows Resistance to Chemo-Immunotherapy
por: Zhao, Qian, et al.
Publicado: (2022)

Comorbidities, clinical intercurrences, and factors associated with mortality in elderly patients admitted for a hip fracture()
por: Edelmuth, Stephanie Victoria Camargo Leão, et al.
Publicado: (2018)

Impact of intercurrent respiratory infections on lung health in infants born <29 weeks with bronchopulmonary dysplasia
por: Taylor, J B, et al.
Publicado: (2013)

Handling death as an intercurrent event in time to recovery analysis in COVID-19 treatment clinical trials
por: Li, Hong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lnfmk7vquancqact358ftfn6el